Şunu aradınız:: tyrosinkinasehæmmere (Danca - İngilizce)

tyrosinkinasehæmmere
inhibitors such as

de fleste tyrosinkinasehæmmere
most tyrosine kinase inhibitors

tyrosinkinasehæmmere, såsom dasatinib og nilotinib, også vincristin og vinblastin
tyrosine kinase inhibitors such as dasatinib and nilotinib, also vincristine and vinblastine

de fleste tyrosinkinasehæmmere sådan som dasatinib og nilotinib, vincristin, vinblastin
most tyrosine kinase inhibitors such as dasatinib and nilotinib, vincristine, vinblastine

reaktivering af hepatitis b i forbindelse med bcr-abl tyrosinkinasehæmmere er beskrevet.
hepatitis b reactivation has been reported in association with bcr-abl tkis.

det aktive stof i iclusig, ponatinib, tilhører lægemiddelgruppen "tyrosinkinasehæmmere".
the active substance in iclusig, ponatinib, belongs to a group of medicines called ‘tyrosine kinase inhibitors’.

i prækliniske sårhelingsmodeller har egfr-selektive tyrosinkinasehæmmere imidlertid vist sig at forsinke sårheling.
however, in preclinical wound healing models egfr selective tyrosine kinase inhibitors were shown to retard wound healing.

det aktive stof i tagrisso, osimertinib, er et kræftlægemiddel af typen "tyrosinkinasehæmmere".
the active substance in tagrisso, osimertinib, is a type of cancer medicine called tyrosine kinase inhibitor.

i modsætning til de fleste andre tyrosinkinasehæmmere er tagrisso aktivt mod kræftceller med mutationen t790m i genet for egfr.
unlike most other tyrosine kinase inhibitors, tagrisso is active against cancer cells with the t790m mutation in the egfr gene.

klassen af tyrosinkinasehæmmere blev identificeret som kraftige hæmmere af cyp1a1, hvor erlotinib og gefitinib udviste den største hæmningsevne in vitro.
the class of tyrosine kinase inhibitors was identified as potent inhibitors of cyp1a1, with erlotinib and gefitinib exhibiting the highest inhibitory potency in vitro.

hvad angår sikkerheden, svarer bivirkningerne af iclusig i det store hele til andre tyrosinkinasehæmmere og kan som regel håndteres ved nedsættelse eller udsættelse af doseringen.
regarding its safety, the side effects with iclusig were largely similar to other tyrosine kinase inhibitors and mostly manageable with dose reduction or dose delay.

medicin mod kræft (f.eks. de fleste tyrosinkinasehæmmere sådan som dasatinib og nilotinib, også vincristin og vinblastin);
anticancer medicines (e.g. most tyrosine kinases inhibitors such as dasatinib and nilotinib, also vincristine and vinblastine);

eftersom nogle tyrosinkinasehæmmere vides at have effekt på qt, skal der udvises forsigtighed, når nintedanib administreres til patienter i risikogruppe for at udvikle qt-forlængelse.
as some other tyrosine kinase inhibitors are known to exert an effect on qt, caution should be exercised when administered nintedanib in patients who may develop qtc prolongation.

medicin mod kræft (f.eks. afatinib, ceritinib, de fleste tyrosinkinasehæmmere sådan som dasatinib og nilotinib, også vincristin og vinblastin);
anticancer medicines (e.g. afatinib, ceritinib, most tyrosine kinases inhibitors such as dasatinib and nilotinib, also vincristine and vinblastine);

dataene vedrørende 52 af patienterne blev anset for at være det vigtigste resultat af undersøgelsen, da andre tyrosinkinasehæmmere ikke ansås for at være egnede, enten fordi de ikke virkede, eller fordi der var risiko for svære bivirkninger.
the data on 52 patients were considered as the main evidence from the study as these patients were identified as having an unmet medical need, because other tyrosine kinase inhibitors were not considered appropriate treatment options for them due to disease resistance or the risk of severe side effects.

quetiapin – bruges til behandling af skizofreni, maniodepressiv sygdom (bipolar sygdom) og moderat til svær depression tyrosinkinasehæmmere – medicin til behandling af kræft
quetiapine - used to treat schizophrenia, bipolar disorder and major depressive disorder tyrosine kinase inhibitors – used as anti-cancer medicines

tagrisso er kun undersøgt hos patienter, der havde mutationen t790m og tidligere havde været behandlet med egfr- tyrosinkinasehæmmere, men tagrisso forventes også at være effektivt hos patienter, der har mutationen t790m og ikke tidligere har fået sådanne lægemidler.
although tagrisso has only been investigated in patients with the t790m mutation who were previously treated with egfr tyrosine kinase inhibitors, tagrisso is also expected to be effective in patients with the t790m mutation who have not previously received these medicines.

imatinib er en protein-tyrosinkinasehæmmer, som potent hæmmer bcr-abl tyrosinkinasen in vitro, in vivo og på cellulært niveau.
imatinib is a protein-tyrosine kinase inhibitor which potently inhibits the bcr-abl tyrosine kinase at the in vitro, cellular and in vivo levels.